| 1 |
Gruessner AC, Gruessner RW. Long-term outcome after pancreas transplantation: a registry analysis[J]. Curr Opin Organ Transplant, 2016，21(4):377-385.
|
| 2 |
Jenssen T, Hartmann A, Birkeland KI. Long-term diabetes complications after pancreas transplantation[J]. Curr Opin Organ Transplant, 2017，22(4):382-388.
|
| 3 |
Heilman RL, Mazur MJ, Reddy KS. Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date[J]. Drugs, 2010，70(7):793-804.
|
| 4 |
Zhang R. Donor-specific antibodies in kidney transplant recipients[J]. Clin J Am Soc Nephrol, 2018，13(1):182-192.
|
| 5 |
Mittal S, Page SL, Friend PJ, et al. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure[J]. Am J Transplant, 2014，14(7):1664-1671.
|
| 6 |
Rudolph EN, Dunn TB, Mauer D, et al. HLA-A, -B, -C, -DR, and -DQ matching in pancreas transplantation: effect on graft rejection and survival[J]. Am J Transplant, 2016，16(8):2401-2412.
|
| 7 |
Salvalaggio PR, Graff RJ, Pinsky B, et al. Crossmatch testing in kidney transplantation: patterns of practice and associations with rejection and graft survival[J]. Saudi J Kidney Dis Transpl, 2009，20(4):577-589.
|
| 8 |
Montgomery RA, Tatapudu VS, Leffell MS, et al. HLA in transplantation[J]. Nat Rev Nephrol, 2018，14(9):558-570.
|
| 9 |
Wiebe C, Nickerson P. Human leukocyte antigen mismatch and precision medicine in transplantation[J]. Curr Opin Organ Transplant, 2018，23(4):500-505.
|
| 10 |
Sypek M, Kausman J, Holt S, et al. HLA epitope matching in kidney transplantation: an overview for the general nephrologist[J]. Am J Kidney Dis, 2018，71(5):720-731.
|
| 11 |
Wiebe C, Kosmoliaptsis V, Pochinco D, et al. A comparison of HLA molecular mismatch methods to determine HLA immunogenicity[J]. Transplantation, 2018，102(8):1338-1343.
|
| 12 |
Daniёls L, Naesens M, Bosmans JL, et al. The clinical significance of epitope mismatch load in kidney transplantation: A multicentre study[J]. Transpl Immunol, 2018，50:55-59.
|
| 13 |
Duquesnoy RJ. Are we ready for epitope-based HLA matching in clinical organ transplantation？[J]. Transplantation, 2017，101(8):1755-1765.
|
| 14 |
McCaughan JA, Tinckam KJ. Donor specific HLA antibodies & allograft injury: mechanisms, methods of detection, manifestations and management[J]. Transpl Int, 2018，31(10):1059-1070.
|
| 15 |
Devos JM, Gaber AO, Teeter LD, et al. Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection[J]. Transplantation, 2014，97(5):534-540.
|
| 16 |
Williams RC, Opelz G, McGarvey CJ, et al. The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors[J]. Transplantation, 2016，100(5):1094-1102.
|
| 17 |
Berney T, Malaise J, Morel P, et al. Impact of HLA matching on the outcome of simultaneous pancreas-kidney transplantation[J]. Nephrol Dial Transplant, 2005，20 (Suppl 2): ii48-ii53.
|
| 18 |
Kandaswamy R, Stock PG, Gustafson SK, et al. OPTN/SRTR 2016 Annual Data Report: Pancreas[J]. Am J Transplant, 2018，18 (Suppl 1):114-171.
|
| 19 |
Jucaud V. The immunogenicity of HLA class Ⅱ mismatches: the predicted presentation of nonself allo-HLA-derived peptide by the HLA-DR phenotype of the recipient is associated with the formation of DSA[J]. J Immunol Res, 2017: 2748614.
|
| 20 |
Cross AR, Lion J, Loiseau P, et al. Donor specific antibodies are not only directed against HLA-DR: minding your Ps and Qs[J]. Human immunology, 2016，77(11):1092-1100.
|
| 21 |
Cantarovich D, De Amicis S, Akl A, et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome[J]. Am J Transplant, 2011，11(12):2737-2746.
|
| 22 |
Tambur AR. Human leukocyte antigen matching in organ transplantation: what we know and how can we make it better (Revisiting the past, improving the future)[J]. Curr Opin Organ Transplant, 2018，23(4):470-476.
|
| 23 |
Heilman RL, Chakkera H, Mazur M, et al. Outcomes of simultaneous kidney-pancreas transplantation with positive cross-match[J]. Transplant Proc, 2009，41(1):303-306.
|
| 24 |
Wiebe C, Rush DN, Nevins TE, et al. Class Ⅱeplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development[J]. J Am Soc Nephrol, 2017，28(11):3353-3362.
|